Clinical and biological prognostic factors in malignant lymphomas

Czech version

Authors: V. Procházka ¹; M. Jarošová ¹; Z. Prouzová ²; M. Geierová ²; T. Papajík ¹; K. Indrák ¹
Authors‘ workplace: Hemato-onkologická klinika Fakultní nemocnice Olomouc a Lékařské fakulty Univerzity Palackého v Olomouci, 2Ústav klinické a molekulární patologie Fakultní nemocnice Olomouc a Lékařské fakulty Univerzity Palackého v Olomouci ¹
Published in: Transfuze Hematol. dnes,19, 2013, No. 2, p. 76-87.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Malignant lymphomas represent a clinically, biologically and genetically varied group of neoplasms. Moreover, the last decade has provided modern haemato-oncology with numerous novel biologically active drugs that have extended therapeutic options and changed our patients’ lives. The era of personalized medicine places new demands on physicians’ decision-making processes. A confident prediction of the patient’s outlook is now an indispensable tool for selecting treatment strategy. Predictive tools, or predictive factors, hand in hand with changes in therapy, have undergone dramatic development. Previous clinical schemes and prognostic indices postulated in the era prior to the introduction of immunotherapy and intensive treatment protocols have limited information value today. Novel prognostic factors are better at reflecting the nature of tumours themselves, allowing estimation of chemo-immunotherapy effectiveness and take into consideration the immune interaction between a tumour and the patient’s organism. Modern molecular cytogenetic and immunohistochemical methods yield important additional prognostic information. The article aims at providing a review of currently used predictive tools, from traditional scores to novel findings in the field of tumour cytogenetics and immunogenomics.

Key words:
lymphoma, prognosis, rituximab, immunotherapy, cytogenetics, immunogenomics

Sources

1. Bloomfield CD, Goldman A, Dick F, et al. Multivariate analysis of prognostic factors in the non-Hodgkin‘s malignant lymphomas. Cancer 1974; 33: 870-9.

2. A predictive model for aggressive non-Hodgkin‘s lymphoma. The International Non-Hodgkin‘s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-94.

3. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology 2010; 28: 2373-2380.

4. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004; 104: 1258-65.

5. Heilgeist A, McClanahan F, Ho AD, et al. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: An analysis of clinical presentation and outcome in 144 patients. Cancer 2013; 119: 99-106.

6. Hoster E, Dreyling M, Klapper W, et al. on behalf of German Low Grade Lymphoma Study Group (GLSG) and European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-65.

7. Gallamini A, Stelitano C, Calvi R, et al. Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-9.

8. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861.

9. Oki Y, Yamamoto K, Kato H, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol 2008; 81: 448-453.

10. Cox MC, Nofroni I, Ruco L, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008; 49: 1745-1751.

11. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–11.

12. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–47.

13. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005; 87: 163-208.

14. Bea S, Zettl A, Wright G, et al; Lymphoma/Leukemia Molecular Profiling Project. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183-90

15. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285-2290.

16. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. NEJM 2002; 346: 1937-1947.

17. Satterwhite E, Sonoki T, Willis TG, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood 2001; 98: 3413-3420.

18. Offit K, Jhanwar SC, Ladanyi M, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin‘s lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer 1991; 3: 189.

19. Bosga-Bouwer AG, Kok K, Booman M, et al. Array comparative genomic hybridization reveals a very high frequency of deletions of the long arm ofchromosome 6 in testicular lymphoma. Genes Chrom Cancer 2006; 45: 976-81.

20. Offit K, Lo CF, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994; 331: 74–80.

21. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. JEM 2006; 203: 315-317.

22. Steidl Ch, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471: 377-383.

23. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106: 4315–21.

24. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000; 95: 2253–61.

25. Bea S, Campo E. Secondary genomic alterations in non-Hodgkin’s lymphomas: tumor-specific profiles with impact on clinical behavior. Haematologica 2008; 93: 641–5.

26. Vater I, Wagner F, Kreuz M, et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol 2009; 144: 317–31.

27. Rubio-Moscardo F, Climent J, Siebert R, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005; 105: 4445–54.

28. Salaverria I, Zettl A, Bea S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expressionbased proliferation signature. J Clin Oncol 2007; 25: 1216–22.

29. Sander S, Bullinger L, Leupolt E, et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. Haematologica 2008; 93: 680–7.

30. Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408–1418.

31. Vegliante MC, Royo C, Palomero J, et al. Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications. PLoS One 2011; 6(6):e21382. doi: 10.1371/journal.pone.0021382.

32. Johansson B, Mertens F, Mitelman F. Cytogenetic evolution patterns in non-Hodgkin’s lymphoma. Blood 1995; 86: 3905–14.

33. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097–9.

34. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006; 13: 1351–9.

35. Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121–32.

36. Dave BJ, Hess MM, Pickering DL, et al. Rearrangements of chromosome band 1p36 in non-Hodgkin’s lymphoma. Clin Cancer Res 1999; 5: 1401–9.

37. d’Amore F, Chan E, Iqbal J, et al. Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. Clin Cancer Res 2008; 14: 7180–7.

38. Hoglund M, Sehn L, Connors JM, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 2004; 39: 195–204.

39. Tilly H, Rossi A, Stamatoullas A, et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 1994; 84: 1043–9.

40. Schwaenen C, Viardot A, Berger H, et al. Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer 2009; 48: 39–54.

41. Bosga-Bouwer AG, Haralambieva E, Booman M, et al. BCL6 alternative translocation breakpoint cluster region associated with follicular lymphoma grade 3B. Genes Chromosomes Cancer 2005; 44: 301–4.

42. Christie L, Kernohan N, Levison D, et al. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: an adverse prognostic indicator? Leuk Lymphoma 2008; 49: 470–6.

43. Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. 4th Edition. IARC: Lyon, 2008; 233-237.

44. Friedberg JW. Double-hit diffuse large B-cell lymphoma. J Clin Oncol. 2012; 30: 3439-43.

45. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of difuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.

46. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 5494-5502

47. Hill BT, Sweetenham J. Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. Leuk Lymphoma 2012; 53(5): 763-769.

48. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patiens with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29: 200-207.

49. Visco C, Li Y, Xu-Monette ZY et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103-2113.

50. Yu B, Zhou X, Li B et al. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma. Ann Hematol 2011; 90: 701-708.

51. Ott G, Ziepert M, Klapper W et al. Immunoblastic morfology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in difuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116: 4916-4925.

52. Ioachim HL, Medeiros LJ. Mantle cell lymphoma. In: Ioachim HL, Medeiros LJ. Lymph Node Pathology. 4th Edition. Lippincott Williams & Wilkins: Philadelphia, 2009; 407-422.

53. Xu W, Li J. SOX11 expression in mantle cell lymphoma. Leuk Lymphoma 2010; 51(11): 1962-1967.

54. Vose JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2012; 604-609.

55. Harris NL, Swerdlow SH, Ott G. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. 4th Edition. IARC: Lyon, 2008; 233-237.

56. Richendollar BG, Pohlman B, Elson P, Hsi ED. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Human Pathol 2011; 42: 552-557.

57. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010; 150: 200-8.

58. Milanovic N, Matkovic S, Ristic D, et al. Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma. J BUON 2012; 17: 497-501.

59. Sibon D, Fournier M, Brière J, et al. Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d‘Etude des Lymphomes de l‘Adulte Trials. J Clin Oncol 2012; 30: 3939-46

60. Procházka V, Faber E, Raida L et al. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma 2012 Jul; 53: 1306-10.

61. Suzuki K, Terui Y, Nakano K, et al. High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone. Leuk Lymphoma 2012; 53: 849-54.

62. Procházka V, Faber E, Raida L, Kapitáňová Z, Langová K, Indrák K, Papajík T Int J Hematol 2012; 96(1): 58–64. High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicularlymphoma independently of the FLIPI score.

63. Goto N, Tsurumi H, Goto H, et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol. 2012; 91: 705-14.

64. Dall´Ozzo S, Tarta S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: infuence of FCGR3A polymorphism on the concentration-effect relationship. Cancer research 2004; 64: 4664-4669.

65. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99: 754-757.

66. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal Clin Oncol 2003; 21: 3940-3947.

67. Prochazka V, Papajik T, Gazdova J, et al. FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma 2011; 58(3): 263-70.

68. Persky DO, Dornan D, Goldman BH, et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated onSWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012; 97: 937-42.

69. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients‘ survival benefit from rituximab. Eur J Haematol 2008: 81(6): 448-53.

70. Porrata LF, Ristow K, Habermann TM, et al. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2008; 84(2): 93-97.

Labels

Haematology Internal medicine Clinical oncology

Separation of whole blood and gravity-based manufacturing of blood components by the disable set ErySet® with a hollow-fibre filter

Recommendations for the diagnosis and treatment of chronic lymphocytic leukaemia

A practical view of the role of HLA matching in unrelated donor haematopoietic stem cell transplantation

Article was published in

Transfusion and Haematology Today

2013 Issue 2